Legend Biotech Corporation

Legend Biotech Corporation is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. Its lead product candidate is ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. Additionally, Legend Biotech is developing allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.

Legend Biotech Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol LEGN. Its shares are traded in US dollars (USD), as the company is headquartered in the United States and its primary exchange is in the US. The company's operations span the United States, China, and Europe, but its stock is denominated in USD.

Legend Biotech operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative cell therapies, particularly CAR-T treatments for cancer. The company's work involves complex biological research and manufacturing processes to create therapies that harness the body's immune system to fight diseases like multiple myeloma and other solid tumors.

Legend Biotech Corporation is headquartered in Somerset, New Jersey, United States. The company was founded in 2014 and operates in the United States, China, and Europe. It serves these regions by developing and commercializing cell therapies for oncology. Its lead product, cilta-cel, is developed in collaboration with Janssen Biotech, Inc., and is aimed at treating multiple myeloma patients globally. The company also has a license agreement with Novartis Pharma AG for CAR-T therapies targeting delta-like ligand protein 3.

Legend Biotech generates revenue primarily through the development and commercialization of cell therapies, with a focus on its lead product cilta-cel (ciltacabtagene autoleucel), a CAR-T therapy for multiple myeloma. The company has a collaboration and license agreement with Janssen Biotech, Inc. (a Johnson & Johnson company) for the development and commercialization of cilta-cel, which likely includes milestone payments, royalties, and profit-sharing. Additionally, Legend Biotech has a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company also has a pipeline of earlier-stage autologous and allogeneic CAR-T and CAR-NK candidates, which may generate future revenue through partnerships or commercialization.